International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(4), P. 2255 - 2255
Published: Feb. 18, 2022
Schistosomiasis,
caused
by
human
trematode
blood
flukes
(schistosomes),
remains
one
of
the
most
prevalent
and
serious
neglected
tropical
parasitic
diseases.
Currently,
treatment
schistosomiasis
relies
solely
on
a
single
drug,
anthelmintic
praziquantel,
with
increased
usage
in
mass
drug
administration
control
programs
for
disease,
specter
resistance
developing
is
constant
threat.
Vaccination
recognized
as
sustainable
options
any
pathogen,
but
despite
discovery
reporting
numerous
potentially
promising
schistosome
vaccine
antigens,
to
date,
no
or
animal
deployment
available.
This
fact
that
Science
ranked
such
an
intervention
top
10
vaccines
need
be
urgently
developed
improve
public
health
globally.
review
summarizes
current
progress
under
clinical
development
advocates
urgent
establishment
revolutionary
effective
anti-schistosome
pipeline
utilizing
cutting-edge
technologies
(including
mRNA
exploiting
CRISPR-based
technologies)
provide
novel
insight
into
future
discovery,
design,
manufacture
deployment.
Vaccines,
Journal Year:
2021,
Volume and Issue:
9(4), P. 390 - 390
Published: April 15, 2021
Increases
in
the
world’s
population
and
density
promote
spread
of
emerging
pathogens.
Vaccines
are
most
cost-effective
means
preventing
this
spread.
Traditional
methods
used
to
identify
produce
new
vaccines
not
adequate,
instances,
ensure
global
protection.
New
technologies
urgently
needed
expedite
large
scale
vaccine
development.
mRNA-based
promise
meet
need.
exhibit
a
number
potential
advantages
relative
conventional
vaccines,
namely
they
(1)
involve
neither
infectious
elements
nor
risk
stable
integration
into
host
cell
genome;
(2)
generate
humoral
cell-mediated
immunity;
(3)
well-tolerated
by
healthy
individuals;
(4)
less
expensive
produced
more
rapidly
processes
that
readily
standardized
scaled-up,
improving
responsiveness
outbreaks.
Multiple
mRNA
platforms
have
demonstrated
efficacy
diseases
treating
several
types
cancers
humans
as
well
animal
models.
This
review
describes
factors
contribute
maximizing
production
effective
transcripts
delivery
systems,
clinical
applications
discussed
detail.
Frontiers in Immunology,
Journal Year:
2021,
Volume and Issue:
12
Published: July 7, 2021
Recently,
mRNA
vaccines
have
become
a
significant
type
of
therapeutic
and
created
new
fields
in
the
biopharmaceutical
industry.
are
promising
next-generation
that
introduced
age
vaccinology.
The
recent
approval
two
COVID-19
(mRNA-1273
BNT162b2)
has
accelerated
vaccine
technology
boosted
pharmaceutical
biotechnology
These
will
help
to
tackle
pandemic
through
immunization,
offering
considerable
hope
for
future
vaccines.
Human
trials
with
data
both
from
cancer
infectious
disease
provided
encouraging
results,
inspiring
industries
focus
on
this
area
research.
In
article,
we
discuss
current
broadly
parts.
first
part,
general
discussed.
We
presented
structure
general,
different
delivery
systems,
immune
response,
clinical
(both
diseases
vaccines).
second
explained.
Finally,
illustrated
snapshot
leading
developers,
challenges,
prospects
Vaccines,
Journal Year:
2022,
Volume and Issue:
10(12), P. 2150 - 2150
Published: Dec. 15, 2022
An
unheard
mobilization
of
resources
to
find
SARS-CoV-2
vaccines
and
therapies
has
been
sparked
by
the
COVID-19
pandemic.
Two
years
ago,
COVID-19’s
launch
propelled
mRNA-based
technologies
into
public
eye.
Knowledge
gained
from
mRNA
technology
used
combat
is
assisting
in
creation
treatments
treat
existing
illnesses
may
avert
pandemics
future.
Exploiting
capacity
create
therapeutic
proteins
impede
or
a
variety
illnesses,
including
cancer,
main
goal
quickly
developing,
highly
multidisciplinary
field
biomedicine.
In
this
review,
we
explore
potential
as
vaccine
using
current
research
findings.
Viruses,
Journal Year:
2022,
Volume and Issue:
14(2), P. 401 - 401
Published: Feb. 15, 2022
In
the
prevention
and
treatment
of
infectious
diseases,
mRNA
vaccines
hold
great
promise
because
their
low
risk
insertional
mutagenesis,
high
potency,
accelerated
development
cycles,
potential
for
low-cost
manufacture.
past
years,
several
have
entered
clinical
trials
shown
offering
solutions
to
combat
emerging
re-emerging
diseases
such
as
rabies,
Zika,
influenza.
Recently,
successful
application
against
COVID-19
has
further
validated
platform
opened
floodgates
vaccine’s
in
disease
prevention,
especially
veterinary
field.
this
review,
we
describe
our
current
understanding
technologies
used
vaccine
development.
We
also
provide
an
overview
developed
animal
discuss
directions
challenges
future
applications
promising
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(4), P. 2255 - 2255
Published: Feb. 18, 2022
Schistosomiasis,
caused
by
human
trematode
blood
flukes
(schistosomes),
remains
one
of
the
most
prevalent
and
serious
neglected
tropical
parasitic
diseases.
Currently,
treatment
schistosomiasis
relies
solely
on
a
single
drug,
anthelmintic
praziquantel,
with
increased
usage
in
mass
drug
administration
control
programs
for
disease,
specter
resistance
developing
is
constant
threat.
Vaccination
recognized
as
sustainable
options
any
pathogen,
but
despite
discovery
reporting
numerous
potentially
promising
schistosome
vaccine
antigens,
to
date,
no
or
animal
deployment
available.
This
fact
that
Science
ranked
such
an
intervention
top
10
vaccines
need
be
urgently
developed
improve
public
health
globally.
review
summarizes
current
progress
under
clinical
development
advocates
urgent
establishment
revolutionary
effective
anti-schistosome
pipeline
utilizing
cutting-edge
technologies
(including
mRNA
exploiting
CRISPR-based
technologies)
provide
novel
insight
into
future
discovery,
design,
manufacture
deployment.
